• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Special therapeutic guidelines from the viewpoint of BfArM (Federal Institute for Drug and Medical Products)].

作者信息

Keller K

机构信息

Bundesinstitut für Arzneimittel und Medizinprodukte, Berlin.

出版信息

Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):669-74.

PMID:9527466
Abstract

Homeopathic, anthroposophic and phytotherapeutic drugs are subject to the German Medicines Act of 1976 (AMG). The relevant EU regulations also refer to this group of medicinal products. Definitions and requirements for proof of adequate quality, efficacy and safety are set out by regulations under national law, as well as EU and WHO regulations. Homeopathic products may be registered without statement of indication. It has become possible in the meantime that medicinal products belonging to these particular schools of therapy and groups of substances are critically reviewed and assessed without being blamed for bias in the sense of discrimination against one of these therapies or exaggerated criticism. The term of "particular schools of therapy and groups of substances" is different from what is understood by "traditional" products according to article 109a AMG. "Traditional" products are subject to reduced requirements and their documentation need not fulfil the assessment criteria established for particular schools of therapy.

摘要

相似文献

1
[Special therapeutic guidelines from the viewpoint of BfArM (Federal Institute for Drug and Medical Products)].
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):669-74.
2
[Special therapeutic processes from the viewpoint of clinical pharmacology].[从临床药理学角度看特殊治疗过程]
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):681-5.
3
[Special therapeutic processes from the viewpoint of the lawyer].[从律师视角看特殊治疗过程]
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):685-90.
4
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
5
[Approval of drugs by national and European agencies--from the viewpoint of drug approval committee A].
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):600-3.
6
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
7
[Differences between clinical trials according to the German law on pharmaceuticals (Arzneimittelgesetz) and trials according to the German law on medical products (Medizinproduktegesetz)].[根据德国药品法(《药品法》)进行的临床试验与根据德国医疗产品法(《医疗产品法》)进行的试验之间的差异]
Ophthalmologe. 2003 Feb;100(2):150-4. doi: 10.1007/s00347-002-0762-2.
8
[Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].[国家和欧洲机构对药品的批准——制药行业的后遗症]
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):596-600.
9
[Regulation of natural medicines in Israel and abroad].[以色列国内外天然药物的监管]
Harefuah. 2000 Nov;139(9-10):339-44, 408, 407.
10
[The regulatory framework for complementary and alternative medicines in Europe].[欧洲补充和替代医学的监管框架]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):771-8. doi: 10.1007/s00103-008-0584-8.

引用本文的文献

1
Whole-systems research in integrative inpatient treatment.综合住院治疗中的全系统研究。
Evid Based Complement Alternat Med. 2013;2013:962729. doi: 10.1155/2013/962729. Epub 2013 Jun 24.